Amanta Healthcare Ltd
Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products.[1]
- Market Cap ₹ 537 Cr.
- Current Price ₹ 138
- High / Low ₹ 155 / 132
- Stock P/E 50.8
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 14.8 %
- ROE 13.0 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 20.7% CAGR over last 5 years
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -22.0%
- The company has delivered a poor sales growth of 8.30% over past five years.
- Company has a low return on equity of 5.80% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 184 | 171 | 225 | 259 | 280 | 275 | |
| 147 | 133 | 173 | 206 | 223 | 215 | |
| Operating Profit | 37 | 38 | 52 | 53 | 58 | 60 |
| OPM % | 20% | 22% | 23% | 20% | 21% | 22% |
| 2 | 1 | 76 | 4 | 1 | 1 | |
| Interest | 38 | 40 | 49 | 35 | 34 | 28 |
| Depreciation | 16 | 17 | 17 | 18 | 20 | 18 |
| Profit before tax | -15 | -18 | 62 | 3 | 5 | 15 |
| Tax % | 25% | 23% | 11% | 179% | 32% | 29% |
| -19 | -22 | 55 | -2 | 4 | 10 | |
| EPS in Rs | -7.03 | -8.14 | 20.54 | -0.79 | 1.35 | 3.64 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 7% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 41% |
| TTM: | 190% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -9% |
| 3 Years: | 6% |
| Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 27 | 27 | 27 | 29 |
| Reserves | 2 | -20 | 36 | 36 | 39 | 68 |
| 231 | 235 | 226 | 216 | 211 | 204 | |
| 127 | 150 | 104 | 96 | 75 | 81 | |
| Total Liabilities | 388 | 392 | 392 | 374 | 352 | 382 |
| 244 | 242 | 240 | 232 | 228 | 217 | |
| CWIP | 0 | 0 | 0 | 9 | 0 | 7 |
| Investments | 0 | 2 | 3 | 0 | 4 | 8 |
| 144 | 149 | 149 | 133 | 120 | 150 | |
| Total Assets | 388 | 392 | 392 | 374 | 352 | 382 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 38 | 33 | 62 | 43 | 58 | 47 | |
| -11 | -16 | -6 | -7 | -10 | -24 | |
| -37 | -18 | -50 | -42 | -46 | -23 | |
| Net Cash Flow | -10 | -0 | 6 | -6 | 1 | -1 |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 104 | 110 | 73 | 75 | 63 | 67 |
| Inventory Days | 225 | 422 | 338 | 247 | 309 | 464 |
| Days Payable | 99 | 186 | 185 | 130 | 129 | 194 |
| Cash Conversion Cycle | 229 | 345 | 226 | 193 | 243 | 336 |
| Working Capital Days | 127 | -5 | 28 | 42 | 16 | 26 |
| ROCE % | 9% | 14% | 13% | 14% | 15% |
Documents
Announcements
-
Board Meeting Outcome for To Approve Unaudited Financial Result For Q1 Of 2025-26
6h - Board approved redemption of 1,00,00,000 RPS at Rs11.742/share (Rs11,74,20,000), approved Sept 26, 2025.
- Result - Financial Results For Q1 Of 2025-26 6h
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 (SEBI Listing Regulations)
7h - Redemption of 1,00,00,000 14% RPS at Rs.11.742 each; aggregate Rs.11,74,20,000 payable from profits.
-
Board Meeting Intimation for Inter-Alia To Consider And Approve Unaudited
Financial Results Of The Company For The Quarter Ended 30Th June, 2025
18 Sep - Board meeting 26 Sep 2025 to approve Q1 (30 Jun 2025) results and consider preference share redemption.
- Closure of Trading Window 12 Sep
Business Profile[1][2]
Amanta Healthcare manufactures sterile liquid products, mainly parenteral medications administered through injections or infusions. Their production utilizes advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM). The company operates in six therapeutic areas, including fluid therapy, ophthalmics, respiratory care, and irrigation solutions, plus a medical device segment.